Title: Glycan: A Target for Diagnosis and Treatment of Brain Tumors
Professor Atit Silsirivanit received his Ph.D. in Medical Biochemistry from Khon Kaen University in 2011. During 2014-2016, he was supported by the Japan Society for the Promotion of Science (JSPS) to pursue postdoctoral training at the Department of Tumor Genetics and Biology, Kumamoto University, Japan. His current position is as an Associate Professor of Biochemistry at the Department of Biochemistry, Faculty of Medicine, Khon Kaen University, Thailand. His research focuses on the involvement of glycans and glycosylation in the development and progression of cancers, including cholangiocarcinoma, glioblastoma, meningioma, and melanoma. We are currently working on 1) The role of glycans and glycosylation in cancer, 2) Identification of glycobiomarkers for cancer diagnosis, monitoring, and prognostic prediction, and 3) Application of lectins for detection of glycobiomarkers.
Dr. Linda Hsieh-Wilson is a Professor of Chemistry at the California Institute of Technology. She was born in New York City and obtained her B.S. degree magna cum laude in chemistry from Yale University in 1990. In 1996, she received her Ph.D. in chemistry from the University of California at Berkeley, where she was a National Science Foundation predoctoral fellow in the laboratory of Professor Peter Schultz. In 1996, she moved to Rockefeller University to study neurobiology with Professor and Nobel Laureate Paul Greengard as a Damon Runyon-Walter Winchell postdoctoral fellow. Hsieh-Wilson joined the faculty at the California Institute of Technology in 2000, where she became an associate professor of chemistry in 2006 and a full professor in 2010. She was an Investigator at the Howard Hughes Medical Institute from 2005-2014, and in 2015, she was elected to the American Academy of Arts and Sciences.
Professor Hsieh-Wilson has pioneered the application of organic chemistry to understand the roles of carbohydrates and protein glycosylation in neurobiology. Her honors include a Beckman Young Investigator Award (2000), Research Corporation Research Innovation Award (2000), Alfred P. Sloan Fellowship (2003), Eli Lilly Award in Biological Chemistry (2006), Arthur C. Cope Scholar Award (2008), Gill Young Investigator Award in Neuroscience (2009), and Horace S. Isbell Award in Carbohydrate Chemistry (2014).
Title: Fingerprinting disease by mass spectrometry
Professor Manfred Wuhrer studied Biochemistry at Regensburg University and obtained his Ph.D. in 1999 at Giessen University, Germany. Subsequently, he joined the Leiden University Medical Center, where he was appointed assistant professor in 2005 and associate professor in 2008. In 2013, he was appointed full professor of Analytics for Biomolecular Interactions at VU University Amsterdam. In 2015 he continued his career as Head of the Center for Proteomics and Metabolomics at LUMC, Leiden. He focuses on the development of mass spectrometric methods for glycomics and glycoproteomics and their application in clinical research and biotechnology. Clinical applications cover the fields of rheumatoid arthritis, inflammatory bowel disease, colorectal cancer, prostate cancer, longevity, as well as various infectious diseases.
Chang Gung Memorial Hospital and University, Taiwan
Title: Cancer immunotherapy targeting glycosphingolipids (GSLs)
Alice L. Yu, MD, PhD, is an Academician of Academia Sinica, Taiwan. She is a Distinguished Chair Professor & Deputy Director of the Institute of Stem Cell & Translational Cancer Research at Chang Gung Memorial Hospital and Professor Emeritus at the University of California in San Diego.
As a pioneer in cancer immunotherapy, Dr. Yu has taken an anti-GD2 monoclonal antibody (Dinutuximab) from preclinical to phase III clinical trial, culminating in its FDA approval for the treatment of high-risk neuroblastoma in 2015. This marks the first immunotherapeutic agent to target glycolipids worldwide. She has continued to improve the efficacy of anti-GD2 immunotherapy through international collaboration. Her group has demonstrated the adverse impact of Globo H expression on the outcome of patients with hepatoma, cholangiocarcinoma, and gallbladder cancer. She also uncovered the roles of Globo H in cancer as an immune checkpoint molecule and angiogenic factor, providing rationales for the ongoing development of Globo H-targeted immunotherapeutics.
She has received many awards, including the Pediatric Oncology Award from the American Society of Clinical Oncology (ASCO) in 2020, Excellence in Technology Transfer Award from Federal Laboratory Consortium (USA) in 2016, The 55th Academic Award from the Ministry of Education (Taiwan), Year 2000 "Key to Life" Award, Leukemia & Lymphoma Society (USA), etc.
Title: A functional study of O-GlcNAcylation on RNA binding protein RBM14
Professor Won Ho Yang received his Ph.D. from Yonsei University, Seoul, Korea, in 2007. After postdoctoral work in the laboratory of Professor Jamey Marth at the UC Santa Barbara, he joined the Department of Systems Biology, Glycosylation Network Research Center, at Yonsei University as an Assistant Professor in 2019. His research interest is understanding the function of protein glycosylation in normal physiology and the pathogenesis of the disease.
Title: Build it to understand it: O-GlcNAc modification plays multiple protective roles against protein amyloid aggregation and pathogenesis
Professor Matthew Pratt received a B.S. in Biochemistry and Mathematics from the University of Arizona in 1999, where he worked for Robin Polt on glycosylation reactions and the synthesis of glycosylated analogs of enkephalin peptides. He then moved to Carolyn Bertozzi' s lab at the University of California Berkeley and focused on the synthesis of complex carbohydrates and the development of chemical tools to analyze glycosylation, receiving a Ph.D. in Chemistry in 2004. He was then an American Cancer Society Postdoctoral Fellow in Tom Muir' s lab at Rockefeller University, where he developed technologies to control proteins in living cells and for the incorporation of modifications into semi-synthetic proteins. He joined the faculty at the Department of Chemistry and Biological Sciences at USC in 2009. His research focuses on the development of bioorthogonal chemical reporters and synthetic proteins to investigate the role of posttranslational modifications, with a particular interest in O-GlcNAc modification.
Title: Quantitative descriptions of structure-function relationships of glycoSHIELD of coronavirus spike proteins
Dr. Danny Hsu is a Research Fellow at the Institute of Biological Chemistry, Academia Sinica. During his doctorate study at Utrecht University, the Netherlands, he determined the atomic structure of a lantibiotic, nisin, in complex with Gram-positive bacterial cell wall precursor, Lipid II. He coined the term "pyrophosphate case" to explain how nisin targets Lipid II to achieve its antimicrobial activity, providing a blueprint for future antibiotics developments. During his postdoctoral research at the University of Cambridge, UK, Danny demonstrated the proof of concept of using solution-state NMR spectroscopy to investigate the co-translational folding of nascent polypeptide chains on the ribosome. His earlier independent research focused on the folding mechanisms and functional implications of topologically knotted proteins. He currently focuses on developing an integrated biophysics and structural biology platform, including cryo-electron microscopy, mass spectrometry, and molecular modeling, to investigate the structure-activity relationship (SAR) of glycoproteins, and coronavirus spike proteins, in particular, and how mutations impact on the SAR in the context of glycosylation.
Title: Glycomics-guided glycoproteomics uncovers new players in the innate immune system
Associate Professor Morten Thaysen-Andersen heads the Analytical Glycoimmunology at Macquarie University, Sydney, Australia. Additionally, he was recently recruited as Visiting Professor at Nagoya University, Japan, to set up a Glycoproteomics lab at the prestigious Institute for Glyco-core Research (iGCORE). Across the two laboratories, his glycobiology-focused research program aims to advance our understanding of the human innate immune system and immune-related diseases, including microbial infections, inflammation, and cancer. His team develops and applies novel glycomics and glycoproteomics technologies using advanced mass spectrometry while drawing on analytical tools in protein and carbohydrate chemistry and methods in immunology, structural biology, microbiology, and molecular and cell biology to unravel fundamental glycobiological processes within the innate immune system.
Title: Mucin Glycans in the Regulation of Microbial Virulence
Professor Ribbeck obtained her Bachelor’s degree and her Ph.D. in Biology from the University of Heidelberg, Germany. She continued her postdoctoral research at the European Molecular Biology Laboratory, Heidelberg, Germany, and the Department of Systems Biology, Harvard Medical School. Professor Ribbeck established her independent research group as a Bauer Fellow at the FAS Center for Systems Biology, Harvard University, in 2007 and joined the Department of Biological Engineering at MIT as an Assistant Professor in 2010.
Her laboratory studies the basic mechanisms of biological hydrogels by which mucus barriers exclude, or allow passage of different molecules and pathogens, and the mechanisms pathogens have evolved to penetrate mucus barriers. It hopes to provide the foundation for a theoretical framework that captures general principles governing selectivity in mucus, and likely other biological hydrogels such as the extracellular matrix, and bacterial biofilms. Her Lab’s work may also be the basis for the reconstitution of synthetic gels that mimic the basic selective properties of biological gels.
Title: Making weak antigens strong: exploiting bacterial outer membrane vesicles for delivering glycans to the immune system
Professor Matthew P. DeLisa is the William L. Lewis Professor of Engineering in the School of Chemical and Biomolecular Engineering at Cornell University. His research focuses on understanding and controlling the molecular mechanisms underlying protein biogenesis--folding and assembly, membrane translocation, and post-translational modifications--in the complex environment of a living cell. He received a B.S. in Chemical Engineering from the University of Connecticut in 1996; a Ph.D. in Chemical Engineering from the University of Maryland in 2001; and postdoctoral work at the University of Texas-Austin, Department of Chemical Engineering. DeLisa joined the Department of Chemical and Biomolecular Engineering at Cornell University in 2003. He has also served as a Gastprofessur at the Swiss Federal Institute of Technology (ETH Zürich) in the Institut für Mikrobiologie. He has garnered a number of honors and awards, including most recently the Biotechnology Progress Award for Excellence in Biological Engineering Publication, and was named the to the inaugural “Life Sciences Power 50” by City & State New York. He is an elected fellow of the American Institute for Medical and Biological Engineering, the American Academy of Microbiology, and the American Association for the Advancement of Science. In recent years, he has served on the IDA/DARPA Defense Science Study Group and the National Academies Committee on Innovative Technologies to Advance Pharmaceutical Manufacturing.
@TAIPEI, AUG 27~SEP 1 2023
Meet our invited speakers for the Glyco26. To learn more about each individual speaker, please click on the photos below. Speakers are arranged by the first alphabet of surname but starting from a randomized alphabet each time.